About: Ludwig Kappos

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Ludwig Kappos Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

researcher, ORCID id # 0000-0003-4175-5509

Attributes	Values
rdf:type	Item
description	forskare (sv) 연구원 (ko) 研究者 (ja) araştırmacı (tr) wetenschapper (nl) дослідник (uk) वैज्ञानिक (hi) изилдөөчү (ky) 研究者 (zh) researcher, ORCID id # 0000-0003-4175-5509 (en)
rdfs:label	Ludwig Kappos (cs) Ludwig Kappos (en) Ludwig Kappos (es) Ludwig Kappos (nl) Ludwig Kappos (ast)
skos:prefLabel	Ludwig Kappos (cs) Ludwig Kappos (en) Ludwig Kappos (es) Ludwig Kappos (nl) Ludwig Kappos (ast)
name	Ludwig Kappos (cs) Ludwig Kappos (en) Ludwig Kappos (es) Ludwig Kappos (nl) Ludwig Kappos (ast)
BDELIS ID	wds:Q57912848-F864B1F4-005E-437D-B9DE-8015D354C8BB
BDELIS ID	79771
given name	wds:Q57912848-71885C3D-3AD7-4A05-A1FA-5F8D88D0F6A5
given name	Ludwig
instance of	wds:Q57912848-2F3D96B4-8A2B-425B-A1B9-6F7F5BFEE0F3
NL CR AUT ID	wds:Q57912848-BF1D8A7F-C105-40D3-BA49-9D33CA59BFCD
instance of	Homo sapiens
NL CR AUT ID	xx0060839
occupation	wds:Q57912848-BB0F7ABE-49D4-47EB-AEAC-E31CE85491D8
employer	wds:Q57912848-44093990-D415-48DB-B11C-C55953E0C5C3 wds:Q57912848-F83D60DA-13DD-47A9-9944-8B7089C0244A
NUKAT ID	wds:Q57912848-FB6AF796-27E4-4DA6-BC3D-06EAE160B38A
sex or gender	wds:Q57912848-5AD8F0E7-25EF-4698-A837-18D1F4F82F3B
ISNI	wds:Q57912848-0AEF62E9-E2E6-45E3-AD1D-69A0FF76C74D
VIAF ID	wds:Q57912848-09513152-1210-4780-9BA2-A9EFD66923C9
GND ID	wds:Q57912848-7f147d54-27f1-4601-bb22-5c63b55e3b18
date of birth	wds:Q57912848-A5B320BA-D927-4A1C-91E3-8702F8DCD6AF
PLWABN ID	wds:Q57912848-5F598E54-45FE-40B6-8260-3C538AEA9D9E
WorldCat Identities ID (superseded)	wds:Q57912848-3EE8465C-D9FB-48C3-9AFD-F198F4EF5261
National Library of Spain ID	wds:Q57912848-404AEB40-F2D5-40B5-83E5-C9522705C3F3
VIAF ID	http://viaf.org/viaf/85693388
GND ID	https://d-nb.info/gnd/12014574X
National Library of Spain ID	http://datos.bne.es/resource/XX5610029
occupation	researcher
employer	University Hospital of Basel University of Basel
NUKAT ID	n2018174301
sex or gender	male
ISNI	0000000078638419
VIAF ID	85693388
GND ID	12014574X
date of birth	1953-01-01 00:00:00Z (xsd:dateTime)
PLWABN ID	9810544546605606
WorldCat Identities ID (superseded)	lccn-no91016036
National Library of Spain ID	XX5610029
ORCID iD	wds:Q57912848-16768735-D6A1-4788-9502-330BC51A33B0
ORCID iD	https://orcid.org/0000-0003-4175-5509
ORCID iD	0000-0003-4175-5509
SNSF person ID	wds:Q57912848-6AA6BF58-2BB4-4221-92D8-C6A5B92D96A2
SNSF person ID	36501
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q57912848
is author of	Meta-analysis of genome scans and replication identify CD6, IRF8 and TNFRSF1A as new multiple sclerosis susceptibility loci Genome-wide association analysis of susceptibility and clinical phenotype in multiple sclerosis Genome-wide meta-analysis identifies novel multiple sclerosis susceptibility loci A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis Anti-MOG antibodies are present in a subgroup of patients with a neuromyelitis optica phenotype Age-dependent B cell autoimmunity to a myelin surface antigen in pediatric multiple sclerosis Lack of association between antimyelin antibodies and progression to multiple sclerosis. Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria Health-related quality of life in multiple sclerosis: effects of natalizumab Oral fingolimod (FTY720) for relapsing multiple sclerosis Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study Extraocular blood flow and endothelin-1 plasma levels in patients with multiple sclerosis Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial Atacicept in multiple sclerosis (ATAMS): a randomised, placebo-controlled, double-blind, phase 2 trial MRI monitoring of immunomodulation in relapse-onset multiple sclerosis trials Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial Varicella-zoster virus infections in patients treated with fingolimod: risk assessment and consensus recommendations for management Long-term safety and effectiveness of natalizumab redosing and treatment in the STRATA MS Study Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab Safety of teriflunomide for the management of relapsing-remitting multiple sclerosis Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trial Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial. Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial. Placebo-controlled trial of oral laquinimod for multiple sclerosis Secondary progressive multiple sclerosis: current knowledge and future challenges Effect of BG-12 on contrast-enhanced lesions in patients with relapsing--remitting multiple sclerosis: subgroup analyses from the phase 2b study Teriflunomide for oral therapy in multiple sclerosis Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study.

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 194 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software